table of content
1 PET Radiopharmaceuticals Market Overview
1.1 Product Overview and Scope of PET Radiopharmaceuticals
1.2 PET Radiopharmaceuticals Segment by Type
1.2.1 Global PET Radiopharmaceuticals Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 F-18
1.2.3 Ru-82
1.2.4 Others
1.3 PET Radiopharmaceuticals Segment by Application
1.3.1 Global PET Radiopharmaceuticals Sales Comparison by Application: (2022-2028)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Others
1.4 Global PET Radiopharmaceuticals Market Size Estimates and Forecasts
1.4.1 Global PET Radiopharmaceuticals Revenue 2017-2028
1.4.2 Global PET Radiopharmaceuticals Sales 2017-2028
1.4.3 PET Radiopharmaceuticals Market Size by Region: 2017 Versus 2021 Versus 2028
2 PET Radiopharmaceuticals Market Competition by Manufacturers
2.1 Global PET Radiopharmaceuticals Sales Market Share by Manufacturers (2017-2022)
2.2 Global PET Radiopharmaceuticals Revenue Market Share by Manufacturers (2017-2022)
2.3 Global PET Radiopharmaceuticals Average Price by Manufacturers (2017-2022)
2.4 Manufacturers PET Radiopharmaceuticals Manufacturing Sites, Area Served, Product Type
2.5 PET Radiopharmaceuticals Market Competitive Situation and Trends
2.5.1 PET Radiopharmaceuticals Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest PET Radiopharmaceuticals Players Market Share by Revenue
2.5.3 Global PET Radiopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PET Radiopharmaceuticals Retrospective Market Scenario by Region
3.1 Global PET Radiopharmaceuticals Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global PET Radiopharmaceuticals Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America PET Radiopharmaceuticals Market Facts & Figures by Country
3.3.1 North America PET Radiopharmaceuticals Sales by Country
3.3.2 North America PET Radiopharmaceuticals Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe PET Radiopharmaceuticals Market Facts & Figures by Country
3.4.1 Europe PET Radiopharmaceuticals Sales by Country
3.4.2 Europe PET Radiopharmaceuticals Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PET Radiopharmaceuticals Market Facts & Figures by Region
3.5.1 Asia Pacific PET Radiopharmaceuticals Sales by Region
3.5.2 Asia Pacific PET Radiopharmaceuticals Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America PET Radiopharmaceuticals Market Facts & Figures by Country
3.6.1 Latin America PET Radiopharmaceuticals Sales by Country
3.6.2 Latin America PET Radiopharmaceuticals Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa PET Radiopharmaceuticals Market Facts & Figures by Country
3.7.1 Middle East and Africa PET Radiopharmaceuticals Sales by Country
3.7.2 Middle East and Africa PET Radiopharmaceuticals Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global PET Radiopharmaceuticals Historic Market Analysis by Type
4.1 Global PET Radiopharmaceuticals Sales Market Share by Type (2017-2022)
4.2 Global PET Radiopharmaceuticals Revenue Market Share by Type (2017-2022)
4.3 Global PET Radiopharmaceuticals Price by Type (2017-2022)
5 Global PET Radiopharmaceuticals Historic Market Analysis by Application
5.1 Global PET Radiopharmaceuticals Sales Market Share by Application (2017-2022)
5.2 Global PET Radiopharmaceuticals Revenue Market Share by Application (2017-2022)
5.3 Global PET Radiopharmaceuticals Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Cardinal Health Inc. (U.S.)
6.1.1 Cardinal Health Inc. (U.S.) Corporation Information
6.1.2 Cardinal Health Inc. (U.S.) Description and Business Overview
6.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
6.1.5 Cardinal Health Inc. (U.S.) Recent Developments/Updates
6.2 Mallinckrodt plc (Ireland)
6.2.1 Mallinckrodt plc (Ireland) Corporation Information
6.2.2 Mallinckrodt plc (Ireland) Description and Business Overview
6.2.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
6.2.5 Mallinckrodt plc (Ireland) Recent Developments/Updates
6.3 GE Healthcare (U.K.)
6.3.1 GE Healthcare (U.K.) Corporation Information
6.3.2 GE Healthcare (U.K.) Description and Business Overview
6.3.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
6.3.5 GE Healthcare (U.K.) Recent Developments/Updates
6.4 Lantheus Medical Imaging, Inc. (U.S.)
6.4.1 Lantheus Medical Imaging, Inc. (U.S.) Corporation Information
6.4.2 Lantheus Medical Imaging, Inc. (U.S.) Description and Business Overview
6.4.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
6.4.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments/Updates
6.5 Bayer AG (Germany)
6.5.1 Bayer AG (Germany) Corporation Information
6.5.2 Bayer AG (Germany) Description and Business Overview
6.5.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
6.5.5 Bayer AG (Germany) Recent Developments/Updates
6.6 Bracco Imaging S.p.A (Italy)
6.6.1 Bracco Imaging S.p.A (Italy) Corporation Information
6.6.2 Bracco Imaging S.p.A (Italy) Description and Business Overview
6.6.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
6.6.5 Bracco Imaging S.p.A (Italy) Recent Developments/Updates
6.7 Eczacibasi-Monrol Nuclear Products (Turkey)
6.6.1 Eczacibasi-Monrol Nuclear Products (Turkey) Corporation Information
6.6.2 Eczacibasi-Monrol Nuclear Products (Turkey) Description and Business Overview
6.6.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
6.7.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments/Updates
6.8 Nordion, Inc. (Canada)
6.8.1 Nordion, Inc. (Canada) Corporation Information
6.8.2 Nordion, Inc. (Canada) Description and Business Overview
6.8.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
6.8.5 Nordion, Inc. (Canada) Recent Developments/Updates
6.9 Advanced Accelerator Applications S.A. (France)
6.9.1 Advanced Accelerator Applications S.A. (France) Corporation Information
6.9.2 Advanced Accelerator Applications S.A. (France) Description and Business Overview
6.9.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
6.9.5 Advanced Accelerator Applications S.A. (France) Recent Developments/Updates
6.10 IBA Molecular Imaging (Belgium)
6.10.1 IBA Molecular Imaging (Belgium) Corporation Information
6.10.2 IBA Molecular Imaging (Belgium) Description and Business Overview
6.10.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2017-2022)
6.10.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
6.10.5 IBA Molecular Imaging (Belgium) Recent Developments/Updates
7 PET Radiopharmaceuticals Manufacturing Cost Analysis
7.1 PET Radiopharmaceuticals Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PET Radiopharmaceuticals
7.4 PET Radiopharmaceuticals Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PET Radiopharmaceuticals Distributors List
8.3 PET Radiopharmaceuticals Customers
9 PET Radiopharmaceuticals Market Dynamics
9.1 PET Radiopharmaceuticals Industry Trends
9.2 PET Radiopharmaceuticals Market Drivers
9.3 PET Radiopharmaceuticals Market Challenges
9.4 PET Radiopharmaceuticals Market Restraints
10 Global Market Forecast
10.1 PET Radiopharmaceuticals Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PET Radiopharmaceuticals by Type (2023-2028)
10.1.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Type (2023-2028)
10.2 PET Radiopharmaceuticals Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PET Radiopharmaceuticals by Application (2023-2028)
10.2.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Application (2023-2028)
10.3 PET Radiopharmaceuticals Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PET Radiopharmaceuticals by Region (2023-2028)
10.3.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
